Anti-amyloid Therapy of Alzheimer’s Disease: Current State and Prospects

S. A. Kozin¹, E. P. Barykin¹, V. A. Mitkevich¹,a*, and A. A. Makarov¹,b

¹Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia
¹e-mail: mitkevich@gmail.com
¹e-mail: aamakarov@eimb.ru
Received May 17, 2018
Revision received June 4, 2018

Abstract—Drug development for the treatment of Alzheimer’s disease (AD) has been for a long time focused on agents that were expected to support endogenous β-amyloid (Aβ) in a monomeric state and destroy soluble Aβ oligomers and insoluble Aβ aggregates. However, this strategy has failed over the last 20 years and was eventually abandoned. In this review, we propose a new approach to the anti-amyloid AD therapy based on the latest achievements in understanding molecular causes of cerebral amyloidosis in AD animal models.

DOI: 10.1134/S0006297918090079

Keywords: Alzheimer’s disease, amyloid-β, isoaspartate, zinc, protein–protein complexes, cerebral β-amyloidosis

ALZHEIMER’S DISEASE: BACKGROUND

Alzheimer’s disease (AD) was for the first time described in 1906 [1]. Currently, it is the most common neurodegenerative pathology affecting more than 44 million people worldwide [2]. It was predicted that by 2050, the number of individuals with AD will increase up to 100 million. Only in Russia, ~1,000,000 patients have been diagnosed with AD [3]. From a psychiatric viewpoint, clinical AD signs are manifested as slowly progressing but steady decline in mental abilities, as well as social and cultural skills, that occurs over 3-10 years starting with inadequate behavior in everyday life (sudden unprovoked aggression, unreasonable emotions, disorientation in space and time, loss of short-term memory, etc.). AD is accompanied with brain tissue degradation that finally results in patient death due to respiratory failure.

Familial AD comprises less than 1% all AD cases and is associated with various mutations [4, 5] resulting in constitutively upregulated expression of β-amyloid (Aβ), a 39-to-43-amino acid peptide with heterogenous C-terminus [6]. The causes of sporadic AD (95% cases) remain unknown; however, it was found that they are closely related to aberrant aggregation of endogenous Aβ. Three major neuromorphological features that can confirm the post mortem diagnosis for all types of AD are (i) extracellular aggregates (amyloid plaques) found in certain brain regions and composed mainly of various Aβ isoforms and metal ions (zinc, copper, and iron), (ii) intracellular neurofibrillary tangles with hyperphosphorylated tau protein as the main component, and (iii) neuronal degeneration [7].

Currently, only symptomatic AD therapy is available that is aimed at overcoming neurotransmitter deficiencies and slowing (on average, for 1-3 years) transition from the state when patients are still capable of tending for their own needs to complete helplessness. There are five drugs approved by the US Food and Drug Administration (FDA) that are currently used in the AD therapy worldwide. They include four cholinesterase inhibitors (Tacrine, Donepezil, Rivastigmine, Galantamine) and one NMDA receptor antagonist (Memantine) [8]. Tacrine was approved by the FDA in 1993, Donepezil in 1996, Rivastigmine in 1998, Galantamine in 2001, and Memantine in 2003. Since 2003, no new anti-AD therapeutic agents have been introduced to the global market; however, the strategies for the AD treatment have been extensively developed based on the knowledge of fundamental mechanisms underlying AD emergence.
PROMISING AGENTS FOR AD THERAPY

At present, 105 potential agents for AD treatment are being investigated in clinical trials, among which 25 undergo phase I trial, 52 – phase II trial, and 28 – phase III trial [9]. Almost all of these trials are sponsored by leading pharmaceutical companies. The majority (70%) of these agents modulate molecular mechanisms underlying AD pathogenesis, i.e., act as disease-modifying agents (DMAs). The remaining 30% are symptom relieving drugs: 14% enhance cognitive functions, 13% act on emotional and behavioral functions, and 3% display a general revitalizing effect unrelated to any biological mechanism [9]. Twelve out of 25 phase I drugs affect aberrant Aβ aggregation; three of them act on tau protein aggregation; nine drugs ameliorate AD symptoms; and for one agent, no mechanism of action was found. Thirty-six out of 52 phase II agents are DMAs, among which 14 are aimed at preventing Aβ aggregation, four act against tau protein aggregation, and one exerts a combined action against both Aβ and tau. Eighteen out of 28 phase III drugs belong to DMAs; three agents improve cognitive functions, whereas seven drugs are aimed at correcting behavioral functions. Among phase III DMAs, 15 agents (including six antibody preparations) target Aβ aggregation, and one acts against tau protein aggregation. Therefore, the majority of currently proposed drug candidates are DMAs mostly represented by antibodies and low-molecular-weight compounds able to prevent aberrant Aβ aggregation via specific binding to endogenous Aβ.

Monoclonal anti-Aβ antibodies currently tested in clinical trials [10, 11] target one of the three epitope classes. Aducanumab [12], Bapineuzumab [13], and GSK933776 [14] recognize Aβ N-terminus; Solanezumab [15] and Crenezumab [16, 17] target the central region of Aβ; Ponezumab [18] binds to the Aβ C-terminus. Gantenerumab [19] recognizes an epitope composed of amino acids located at the N-terminus and the central fragment of Aβ. These antibodies have different binding specificity toward Aβ aggregates. In particular, Aducanumab and Gantenerumab bind mainly to aggregated Aβ, whereas Solanezumab selectively binds to soluble Aβ monomers. In contrast, Bapineuzumab and Crenezumab bind with a high affinity to oligomeric Aβ. X-ray crystallography analysis of antibody complexes with Aβ revealed additional epitopes that could be also considered promising pharmaceutical targets [20]. Depending on the Aβ oligomerization pathway, the structure of Aβ aggregates may vary [21, 22]. However, the primary building unit in any type of aggregates is a U-shaped (hairpin) Aβ molecule. Hydrophobic residues including Phe19, Phe20 and Ile34, connect two strands of the polypeptide chain, while a salt bridge between Asp23 and Lys28 stabilizes the structure [23-26]. So far, Crenezumab is the only antibody targeting the middle portion of the Aβ peptide that can bind to several Aβ aggregate forms and cause their dissociation.

Various short peptides and peptidomimetics are also used for targeted Aβ binding and prevention of its aggregation [27]. However, unlike the monoclonal antibody-binding sites, the Aβ regions responsible for the binding of these compounds have not been precisely identified [28-30]. Propanesulfonic acid derivative Alzhemed (Tramiprosate) [31] is the most studied low-molecular-weight anti-aggregation peptidomimetic used for AD treatment. It has been designed to bind with a high affinity to the HHQK motif (a.a. 13-16) responsible for the Aβ interaction with microglial cells and presumably, for Aβ aggregation [32]. Despite the fact that Alzhemed demonstrated high efficacy in experiments [33], it turned out to be inapplicable as an anti-AD agent [34].

ANTI-AMYLOID THERAPY TARGETING THE 1-16 FRAGMENT OF Aβ

According to the commonly accepted amyloid hypothesis, AD pathogenesis is triggered by the formation of soluble neurotoxic oligomers from physiologically monomeric Aβ molecules followed by the generation of insoluble polymeric Aβ aggregates eventually accumulated as amyloid plaques [35]. Prevention of cerebral amyloidogenesis via inhibiting pathological Aβ oligomerization (anti-amyloid therapy) is considered the most promising strategy for AD treatment [36]. Dimerization of monomeric Aβ is a prerequisite for aggregate formation. It was found that Aβ dimers are neurotoxic, and their serum levels in AD patients correlate with clinical manifestation of the disease [37, 38]. Therefore, targeted blockade of Aβ dimerization might be the most efficient way for preventing amyloidogenesis. Obviously, Aβ in its natural conformation is not a pathogenic molecule, thereby suggesting that AD pathological cascade is initiated by some additional factors.

The driving forces behind Aβ pathological aggregation remain unknown; however, it was found that a crucial role in this process belongs to zinc ions [39]. Human Aβ binds zinc ion via its metal-binding domain 1-16 (Aβ1-16) [40, 41]. This domain contains the 11-14 motif required for zinc-induced Aβ dimerization [42] resulting in the formation of stable Aβ aggregates with parallel β-sheet arrangement of the monomers [43]. Note that in amyloid plaques, Aβ amino acids 17-42 (Aβ17-42) constitute a hydrophobic core consisting of β-sheets and β-turns, whereas residues 1-16 are located outside this core and do not participate in the amyloid plaque stabilization [44]. However, the hydrophobic fragment Aβ17-42 per se does not form amyloid aggregates in vivo [45, 46]. The metal-binding domain in rat and mouse Aβ contains three amino acid substitutions (Arg5Gly, Tyr10Phe, and His13Arg) that distinguish this protein from other mam-
malian β-amyloids and are presumably associated with the resistance of these rodents to AD-like neurodegenerative pathologies [47]. Altogether, these facts indicate the key role of the metal-binding domain 1-16 in cerebral amyloidogenesis in AD [41, 48-55].

For the first time, the ability to induce cerebral amyloidogenesis of Aβ aggregates isolated post mortem from AD patients was demonstrated in monkeys injected intracerebrally with homogenates of the autopsied AD patients’ brain [56, 57] (Fig. 1). Later, a series of studies in animal AD models [58-61] found that the molecular agent causing accumulation of pathological amyloid plaques in brain tissues is one of the conformational (or chemically modified) Aβ variants [62-64]. However, the precise molecular nature of this variant remained unknown [65]. It was suggested that it can be Aβ phosphor ylated at serine 8 residue, pyroglutamylated at position 3 [66, 67], or non-covalently bound to other biomolecules [35]. Chemically modified Aβ isoforms with altered ability to interact with zinc ions [68] could be of special interest as potential molecular targets and/or biomarkers in AD therapy and diagnostics [48-51, 69-71].

After the Aβ fragment 1-16 was identified as a zinc-binding domain [41, 72-74], its conformation in the absence or presence of zinc ions has been established [75]. It was found that interaction of zinc ions with Aβ proceeds in two stages [76]. First, zinc ions are bound by the side chains of Glu11, His13, and His14 of the pre-structured motif 10-15. Next, the side chain of His6 enters the zinc ion coordination sphere, which results in the emergence of ordered compact structure including the entire fragment 1-16 complexed with a single zinc ion. It was determined that the Aβ motif 11-14 (Glu-Val-His-His) not only acts as a primary zinc-ion recognition site [75, 76], but also controls zinc-induced Aβ oligomerization [42, 77, 78], while His13 plays a crucial role in the zinc-induced Aβ aggregation [79]. The spatial structure of the 11-14 motif is very rigid and remains virtually unchanged in both intact and zinc-bound Aβ [75, 80]. The secondary structure of this motif is represented by the left-handed polyproline II helix [81] (left-handed helices are known to be involved in protein—protein interactions [82]). Collectively, these properties (zinc binding, conserved structure, and predisposition to interact with biomolecules) make the motif 11-14 an important structural and functional determinant of Aβ.

Recently, the molecular mechanism for the zinc-dependent oligomerization of human Aβ metal-binding domains was described [83, 84] (Fig. 2). First, a monomeric zinc—metal-binding domain complex is

---

**Fig. 1.** Animals (monkeys and transgenic mice) intracerebrally injected with brain homogenate from AD patients develop Alzheimer-like neuropathology [56-63]. Amyloid plaques contained Aβ and its modified species, other proteins (ApoE, C1q, laminins, etc.), and metals (Cu, Zn, Fe). Intracerebral administration of Aβ, Aβ dimers, Aβ oligomers, Aβ + Zn/Cu, or Aβ + ApoE fails to induce amyloidosis in the injected animals [64], whereas isoAβ administered intravenously accelerates development of cerebral β-amyloidosis in mice [91].
assembled, in which zinc ion is coordinated by His6, Glu11, His13, and His14. Then, the two domains form a dimer with a single zinc ion coordinated by Glu11 and His14 of the interacting domains. This dimerization is followed by the conformational transition of motifs 6-14 in each subunit resulting in the formation of the second zinc-binding site involving His6 and His13, so the dimer becomes a seed for further zinc-dependent oligomerization proceeding in a chain reaction manner. Each domain in the developing oligomer preserves its initial conformation [83]. Such domain structure allows each Aβ molecule to bind two other Aβ molecules through zinc ions. Isomerization of Asp7 plays an important role in this potentially pathogenic process [51], because it significantly increases the ability of Aβ metal-binding domain 1-16 to undergo zinc-dependent oligomerization due to intramolecular conformational changes that provide a steric opportunity for the motif 11-14 to interact with other Aβ molecules [68, 85]. Zinc-induced oligomerization of intact Aβ may be initiated by the formation of zinc-dependent heterodimers between intact and isomerized Aβ molecules via motifs 11-14 of the interacting subunits [85]. Therefore, targeted blockade of this motif should significantly slow down or even prevent zinc-induced Aβ oligomerization and, subsequently, cerebral amyloidogenesis.

Development of amyloid plaques in the brain (cerebral amyloidogenesis) is one of the major symptoms of AD pathogenesis. In experimental animals, cerebral amyloidogenesis can be significantly accelerated by injecting brain homogenates from AD patients [86]. More than 50% Aβ molecules in amyloid plaques contain isomerized Asp7 residue (isoAβ molecules) [87, 88]. IsoAβ can spontaneously form from synthetic Aβ peptides [75, 89]. Based on the results of [65, 90], it may be expected that isoAβ acts as a seed of pathological oligomerization and aggregation of physiologically normal endogenous Aβ molecules. Indeed, it was shown that intravenous administration of synthetic isoAβ1-42 results in significantly accelerated cerebral amyloidogenesis in B6C3-Tg(APPswe,PSEN1-dE9)85Dbo/j mice (AD model) [91] known to develop a significant amount of cerebral amyloid plaques at the age of 4 to 6 months. In these mice, accumulation of amyloid plaques correlates with the development of cognitive dysfunctions [92, 93]. It was found that isoAβ1-42 is toxic for neuronal cells [94, 95]. Therefore, isoAβ1-42 is the most plausible AD pathogenic agent, and its appearance in the blood serum (presumably, due to spontaneous protein aging) results in the formation of neurotoxic oligomers of endogenous Aβ [91]. The isoAβ1-42 domain 1-16 in was found to be necessary and sufficient for inducing cerebral amyloidogenesis after its administration to experimental animals [52, 91]. The data on the crucial role of motif 1-16 in Aβ oligomerization [43, 47, 85] and the fact that it represents an independent structural domain in Aβ [41, 44, 75, 80] make the motif 1-16 the major pharmaceutical target in the anti-amyloid AD therapy [55].

α4 NICOTINIC ACETYLCHOLINE RECEPTOR FRAGMENT AS A POTENTIAL ANTI-AMYLOID DRUG

Considering that zinc-induced oligomerization of intact Aβ may be initiated by the formation of zinc-dependent heterodimers between intact and isomerized Aβ molecules via the motifs 11-14 (Glu11-Val12-His13-His14) of the interacting subunits [85], targeted blockade of this motif should significantly slow down or even prevent zinc-induced Aβ oligomerization and, therefore, cerebral amyloidogenesis. Potential agents capable of specific binding of motif 11-14 include antibodies, low-molecular-weight compounds, peptides, peptidomimetics, and other substances. Passive immunotherapy is widely used in today medicine; for a long time, it has been considered a promising approach to the anti-amyloid therapy in AD. Currently, several antibodies (Bapineuzumab,
Gantenerumab, Aducanumab) are available that hinder interactions of the motif 11-14, thereby preventing Aβ aggregation and causing disintegration of already existing amyloid plaques [96]. However, clinical trials demonstrated that these antibodies are toxic and can even aggravate neuronal dysfunction [97].

It is known that Aβ interacts with acetylcholine receptors. The critical role in this interaction belongs to the motif 11-14; although the Aβ-binding site in the receptor has not been identified yet [98]. Bioinformatic analysis showed that the extracellular domain of the nicotinic acetylcholine receptor (α4 subunit) contains a potential interaction partner of Aβ — the fragment His-Ala-Glu-Glu (HAEE) complementary to the Aβ motif 11-14 and conserved in humans, mice, and chicken [99, 100].

It was found that synthetic peptide acetyl-His-Ala-Glu-Glu-NH₂ (Ac-HAEE-NH₂) specifically binds to the motif 11-14 in the Aβ metal-binding domain 1-16, thereby blocking zinc-induced domain dimerization and hindering aggregation of the full-size Aβ in vitro [99, 100]. Intravenously injected Ac-HAEE-NH₂ slowed down cerebral amyloidogenesis in B6C3-Tg(APPswe,PSEN1-dE9)85Dbo/j mice (AD model): average number of amyloid plaques per brain section decreased from 14.2 ± 3.1 (control group) to 5.8 ± 2.1 (treated group) [100]. Based on this parameter, the efficacy of Ac-HAEE-NH₂ was significantly higher than that of the anti-amyloid drug Alzhemed (Tramiprosate), one of the best-known candidates for AD treatment [101]. It was found that in TgCRND8 mice, Alzhemed decreased the amount of amyloid plaques by 30% as compared to the control group [31].

INHIBITION OF METAL-DEPENDENT INTERACTIONS OF Aβ ISOFORMS WITH PARTNER PROTEINS AS A NEW APPROACH TO THE ANTI-AGGREGATION THERAPY OF AD

We believe that the failure of clinical trials with the anti-amyloid agents developed over the last 20 years is related to the shortcomings in our understanding of molecular mechanism involved in the initiation of pathological aggregation of endogenous Aβ. According to the commonly accepted hypothesis, the primary process triggering pathological AD cascade is the appearance of soluble toxic Aβ oligomers [54] (Fig. 3). It is believed that any molecule of endogenous Aβ can spontaneously adopt

Fig. 3. Classical and isoAβ-dependent models of amyloidogenesis. According to the classical model, amyloid plaque development results from the oligomerization of soluble Aβ with subsequent formation of insoluble Aβ fibrils on the neuronal cell surface [54]. The amyloidogenesis model proposed by us assumes the presence of a pathogenic agent — modified isoAβ peptide, whose percentage content increases with age [104]. IsoAβ induces amyloidogenesis in model mouse strains [52, 91] due to the formation of amyloid matrix, which is an isoAβ–Zn²⁺—neuronal receptor complex that serves as a seed for developing amyloid aggregates [100].
the pathological conformation, so that its interaction with other Aβ molecules would result in the formation of pathological amyloid aggregation [65, 86, 90, 102]. Hence, prototypic anti-amyloid agents were expected to maintain Aβ in its monomeric state and/or to destroy existing amyloid plaques [103]. However, the inefficacy of standard anti-aggregation therapy indicates that neurotoxic oligomers do not appear spontaneously, but rather emerge under the influence of certain factors. The data indicating the existence of such amyloidogenesis mechanisms have been obtained during the last few years: (i) cerebral amyloidogenesis is caused by structurally and/or chemically modified Aβ isoforms [52, 64, 91]; (ii) the level of isomerized Asp7-bearing Aβ in patients with AD is elevated [104]; (iii) pathogenic prion-like seeds of Aβ aggregation can spread via peripheral circulation [91, 105]; (iv) interaction with zinc ions is necessary for cerebral amyloidogenesis [39, 106]; (v) metal-mediated interactions of Aβ with neuronal receptors may play a substantial role in neurodegeneration [98, 107-113].

Based on these data, the following molecular mechanism for the initiation of pathological Aβ aggregation in AD was proposed (Fig. 3). The process starts with the emergence of chemically modified peptide species – isoAβ – in the blood serum (e.g., due to spontaneous aging or neurotrauma). Then, isoAβ enters brain tissues and interacts with neuronal cell receptors in a zinc-dependent manner. As a result, isoAβ forms high-affinity zinc-containing complexes with neuronal receptors (amyloid matrices) that serve as seeds of pathological Aβ aggregation. When interacting with the amyloid matrix, endogenous Aβ loses its native conformation and forms aggregates via the zinc-dependent oligomerization mechanism resulting in the formation of insoluble amyloid plaques that exist in a dynamic equilibrium with soluble Aβ oligomers. These oligomers serve as the amyloid matrix on the neuronal cell surface, as well as independent seeds of aggregation in the extracellular space.

Based on the proposed mechanism, we suggest a new strategy for AD anti-amyloid therapy (Fig. 4). Typically, anti-aggregation therapy with monoclonal antibodies is aimed at the destruction of amyloid plaques and Aβ oligomers. The new strategy considers amyloid matrix as the major therapeutic target and implies disruption of zinc-dependent complexes between Aβ and receptors. The efficacy of such therapy was demonstrated in the experiments using peptide HAEE, a competitive inhibitor of interaction between Aβ and α4 nicotinic acetylcholine receptor [100].

Recent advances in understanding the molecular causes of the emergence of AD pathological conditions have led to the hypothesis on the crucial role of zinc-mediated interactions between Aβ isoforms and neuronal receptors in the AD development. These interactions result in the formation of complexes on the neuronal membrane that serve as an amyloid matrix. Binding of endogenous Aβ to the amyloid matrix results in its transformation into neurotoxic oligomers and amyloid plaques. Amyloid matrix is a conceptually new type of pharmaceutical target for the development of anti-amyloid agents for AD therapy.

**Funding**

The study was supported by the Russian Science Foundation (project no. 14-24-00100).

**REFERENCES**


of Alzheimer’s disease amyloid β(1-16) peptide, 
Biochemistry, 9, 1564-1567.


Chembiochem, 6, 1663-1671.

Int. J. Mass Spectrom., 228, 999-1016.


Metallomics, 7, 422-425.

Mol. BioSyst., 10, 2590-2596.

79. Liu, S.-T., Howlett, G., and Barrow, C. J. (1999) Histidine-13 is a crucial residue in the zinc ion-induced aggregation of the Aβ peptide of Alzheimer’s disease, 
Biochemistry, 38, 9373-9378.

Proteins, 81, 1748-1758.


BIOCHEMISTRY (Moscow) Vol. 83 No. 9 2018